PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...

MethylScan is a low-cost blood test that detects multiple cancers and liver diseases by analyzing DNA methylation patterns ...

The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023.  The ...

PanGIA Biotech, Inc. ("PanGIA") announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine Learning Assay Detects Prostate Cancer," (1) demonstrating clinical validation ...

A breakthrough in microbiome research could change how colorectal cancer is detected—no colonoscopy required. Scientists used AI to map gut bacteria at an unprecedented level of detail, revealing ...

The Gyne Cancer Company™ — today announced the publication of peer-reviewed evidence demonstrating that molecular signals ...

Final random-forest-based models outperformed all publicly available risk scores on internal and external test sets.

A new study reveals that gut bacteria and metabolites may hold the key to detecting serious digestive diseases earlier and more easily. Using AI, scientists found that biomarkers linked to one ...

MethylScan is a low-cost blood test that detects cancers and organ diseases by analyzing DNA methylation, improving early diagnosis, and identifying disease origin.

New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and ...